Largest FDA Study of High-Risk PCI Patients Shows Improved Outcomes with Impella® Heart Pumps
Jeffrey J. Popma, MD, presents the latest data from the PROTECT series clinical study...
New Data from NCSI Demonstrates 72% Survival with 98% Native Heart Recovery
New data from the National Cardiogenic Shock Initiative Study (NCSI) on 171 consecutive AMI cardiogenic shock (AMICS) patients...
For Best Outcomes in AMI Cardiogenic Shock, Place Impella 2.5® or Impella CP® Pre-PCI
A preponderance of evidence from the FDA cVAD Study, Impella Quality Assurance Database and physician-initiated National Cardio...
Dr. O’Neill’s IQ Data and AMICS Presentation from TCT 2018
Adoption of best practices improves survival for patients with Acute Myocardial Infarction and Cardiogenic Shock (AMICS) suppor...
Renal Effects of Impella Support During Protected PCI
Dr. Michael P. Flaherty's TCT 2018 presentation on Renal Effects of Impella support during Protected PCI....
Analysis of Outcomes for 15,259 U.S. Patients with AMICS Supported with the Impella Device
Dr. William O’Neill outlines his recent publication of 15,529 AMI cardiogenic shock patients from the Impella Quality (IQ) da...
